
ABEO
USDAbeona Therapeutics Inc. Common Stock
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$4.150
Kõrge
$4.239
Madal
$4.000
Maht
0.89M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
215.4M
Tööstusharu
Biotehnoloogia
Riik
United States
Kauplemisstatistika
Keskmine maht
1.15M
Börs
NCM
Valuuta
USD
52 nädala vahemik
Tehisintellekti analüüsiaruanne
Viimati uuendatud: 31. okt 2025ABEO Stock Analysis: Abeona Therapeutics Inc. - A Biotech Investment Crossroads
Recent News & Sentiment
- Key Development (Oct 30, 2025): Abeona announced a permanent J-Code for its gene therapy ZEVASKYN®, critical for enhancing reimbursement access and commercial viability. This follows months of uncertainty after the stock peaked at $7.54 (Sep 15) and crashed to $4.97 (Oct 30), shedding 34% from its 52-week high.
- Market Reaction: Despite positive news, the stock closed +1.8% on Oct 30 ($5.08 from $4.99), with volume tripling to 3.9M shares (vs. avg 970K). This suggests polarized investor sentiment - some buying on optimism, others fleeing prior losses.
Price Action Breakdown
- Three-Month Trend:
- Bullish Spike: Sharp 13.6% surge on Aug 14 ($6.77→$7.27) amid heavy volume (1.5M+ shares), hinting at speculative interest.
- Bearish Slide: Steady decline from $7.27 to $5.28 (Oct 28), followed by a sudden 5.5% dip on Oct 29 ($5.26→$4.97) - the lowest close since Jul 31.
- Critical Support Zone: Current price hovers near $5.03, the lower Bollinger Band threshold. Technical indicators conflict:
- Bullish: OBV (On-Balance Volume) surged 7.2x above average, signaling accumulation.
- Bearish: DMI confirms a downtrend (-DI 15.1 > +DI 7.7), while MACD remains below its signal line, warning of continued pressure.
Strategic Outlook
- AI Projections: Models predict +1.3% (Day 1), +1.0% (Day 2), +1.8% (Day 3), aiming for a potential $5.26 target. Confidence levels aren't specified, but the upward bias aligns with the recent J-Code catalyst.
- Valuation Contradictions:
- Positive: P/E ratio (7.9x) trails the sector's 11.9x average, and ROE (48.3%) outperforms benchmarks.
- Negative: Debt-to-Equity ratio (14.72) sits far above acceptable thresholds (threshold 0.70), raising solvency concerns.
Recommendations
1. Short-Term Tactical Buy (Neutral Bias):
- Entry Points: $5.02-$5.09 (current close at $5
Seotud uudised
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CLEVELAND, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in
Abeona Therapeutics® Announces Permanent J-Code for ZEVASKYN® (prademagene zamikeracel)
CLEVELAND, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announced that the
Tehisintellekti ennustusBeta
Tehisintellekti soovitus
Uuendatud kell: 10. nov 2025, 13:08
66.0% Kindlus
Risk ja kauplemine
Sisenemispunkt
$4.18
Võta kasum
$4.48
Peata kahjum
$3.79
Põhitegurid
Seotud aktsiad
WDI
Western Asset Diversified Income Fund Common Shares of Beneficial Interest
AMED
Amedisys Inc
RBCAA
Republic Bancorp Inc.
IGI
Western Asset Investment Grade Defined Opportunity Trust Inc.
NTGR
NETGEAR Inc.
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.